DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» PPAR agonist
PPAR agonist
Muraglitazar Bristol-Myers Squibb/Merck Daniella Barlocco
7-Azaindoles and Their Use As Ppar Agonists 7-Azaindole Und Ihre Verwendung Als Ppar-Agonisten 7-Azaindoles Et Leur Utilisation Comme Agonistes De Ppar
The Leading Source of Diabetes Business News the Long View Fall
S 26948: a New Specific Peroxisome Proliferator–Activated Receptor
Role of Dual PPAR Gamma and Alpha Agonists in Diabetes Mellitus
George Grunberger, M.D., F.A.C.P., F.A.C.E
Oral Hypoglycemic Drugs in the Management of Type 2 Diabetes Mellitus: a Review
(12) United States Patent (10) Patent No.: US 9,533,022 B2 Mehta Et Al
09.Subjectindex ADA 13.Indd
(PPAR) Agonists Activate Hepatitis B Virus Replication in Vivo Lingyao Du, Yuanji Ma, Miao Liu, Libo Yan and Hong Tang*
The Pparγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth Through an Immune-Mediated Mechanism
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly Ppara Agonist with Moderate Pparc Agonist Activity in Healthy Human Subjects
Untersuchungen Zur Regulation Des Lipid- Und Energiestoffwechsels Durch Den Peroxisomenproliferator-Aktivierten Rezeptor Α
2020 Diabetes Guideline Data Supplement
Current Status of Carcinogenicity Assessment of Peroxisome
Activation Prevents Diabetes in OLETF Rats Comparison with PPAR
Potentiation of Insulin Signaling in Tissues of Zucker Obese Rats After
A New Thiazolidinedione, NC-2100, Which Is a Weak PPAR
Top View
(PPAR) Agonists in Substance Use Disorders: a Synthesis of Preclinical and Human Evidence
Data Supplement
Evaluating the Cardiovascular Safety of New Medications for Type 2
PPAR Agonist Fenofibrate Suppresses Tumor Growth Through Direct
Effectiveness of the PPAR Agonist Saroglitazar in Nonalcoholic Steatohepatitis: Positive Data from Preclinical & Clinical Studies
PPAR Agonists and Metabolic Syndrome: an Established Role?
GLP-1 RA Should I Try
Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
PPAR-Mediated Toxicology and Applied Pharmacology
Pparα Agonist Oral Therapy in Diabetic Retinopathy
16725.Full.Pdf
Combination of PPAR-Α Agonist and DPP-4 Inhibitor
Independent Mechanisms Γ Lymphoma Apoptosis by PPAR
Scaffold-Based Discovery of Indeglitazar, a PPAR Pan-Active Anti-Diabetic Agent
Peroxisome Proliferator–Activated Receptor
Fibrates, Glitazones and Peroxisome Proliferator-Activated Receptors Fanny Lalloyer1,2,3,4 and Bart Staels1,2,3,4
Process Development and Scale-Up of the PPAR Agonist NNC 61-4655
Pioglitazone Increases Serum DPP-4 Level in Type 2 Diabetes Mellitus